Susceptibility profile of echinocandins, azoles and amphotericin B against yeast phase of Talaromyces marneffei isolated from HIV-infected patients in Guangdong, China
- 66 Downloads
Talaromyces marneffei (T. marneffei) can cause talaromycosis, a fatal systemic mycosis, in patients with AIDS. With the increasing number of talaromycosis cases in Guangdong, China, we aimed to investigate the susceptibility of 189 T. marneffei clinical strains to eight antifungal agents, including three echinocandins (anidulafungin, micafungin, and caspofungin), four azoles (posaconazole, itraconazole, voriconazole, and fluconazole), and amphotericin B, with determining minimal inhibition concentrations (MIC) by Sensititre YeastOne™ YO10 assay in the yeast phase. The MICs of anidulafungin, micafungin, caspofungin, posaconazole, itraconazole, voriconazole, fluconazole, and amphotericin B were 2 to > 8 μg/ml, >8 μg/ml, 2 to > 8 μg/ml, ≤ 0.008 to 0.06 μg/ml, ≤ 0.015 to 0.03 μg/ml, ≤ 0.008 to 0.06 μg/ml, 1 to 32 μg/ml, and ≤ 0.12 to 1 μg/ml, respectively. The MICs of all echinocandins were very high, while the MICs of posaconazole, itraconazole, and voriconazole, as well as amphotericin B were comparatively low. Notably, fluconazole was found to have a higher MIC than other azoles, and exhibited particularly weak activity against some isolates with MICs over 8 μg/ml. Our data in vitro support the use of amphotericin B, itraconazole, voriconazole, and posaconazole in management of talaromycosis and suggest potential resistance to fluconazole.
KeywordsAntifungal susceptibility Talaromyces marneffei HIV positive Echinocandin Azole Sensititre YeastOne
We thank Thomas Fitzpatrick (University of Washington School of Medicine) for the language organization and editing.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical statement and informed consent
This study was approved by the institutional review board of Guangzhou Eighth People’s Hospital, which contained only sub-cultured clinical T. marneffei isolates and all patient information were anonymised. Informed consent was not required in this work.
- 3.Peng J, Chen Z, Cai R, Huang X, Lin L, Liang W, Xiong Z, Chen J, Chen H, Yang Y, Liu S, Jiang Q (2017) Recovery from Talaromyces marneffei involving the kidney in a renal transplant recipient: a case report and literature review. Transpl Infect Dis 19(4). https://doi.org/10.1111/tid.12710
- 5.Le T, Wolbers M, Chi NH, Quang VM, Chinh NT, Lan NP, Lam PS, Kozal MJ, Shikuma CM, Day JN, Farrar J (2011) Epidemiology, seasonality, and predictors of outcome of AIDS-associated Penicillium marneffei infection in Ho Chi Minh City, Viet Nam. Clin Infect Dis 52(7):945–952. https://doi.org/10.1093/cid/cir028 CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Masur H, Brooks JT, Benson CA, Holmes KK, Pau AK, Kaplan JE, National Institutes of H, Centers for Disease C, Prevention, America HIVMAotIDSo (2014) Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: updated guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 58(9):1308–1311. https://doi.org/10.1093/cid/ciu094 CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Li HR, Cai SX, Chen YS, Yu ME, Xu NL, Xie BS, Lin M, Hu XL (2016) Comparison of Talaromyces marneffei infection in human immunodeficiency virus-positive and human immunodeficiency virus-negative patients from Fujian, China. Chin Med J 129(9):1059–1065. https://doi.org/10.4103/0366-6999.180520 CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD (2016) Clinical practice guideline for the Management of Candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 62(4):e1–50. https://doi.org/10.1093/cid/civ933 CrossRefPubMedGoogle Scholar
- 14.Chaiwarith R, Supparatpinyo K (2016) Talaromyces (Penicillium) marneffei and HIV.1–9. https://doi.org/10.1007/978-1-4614-9610-6_419-1
- 16.Lau SKP, Lo GCS Lam CS, Chow WN, Ngan AH, Wu AK, Tsang DN, Tse CW, Que TL, Tang BS, Woo PC (2017) In vitro activity of posaconazole against Talaromyces marneffei by broth microdilution and Etest methods and comparison to itraconazole, voriconazole, and anidulafungin. Antimicrob Agents Chemother 61 (3). https://doi.org/10.1128/AAC.01480-16
- 17.Alexander BD, Byrne TC, Smith KL, Hanson KE, Anstrom KJ, Perfect JR, Reller LB (2007) Comparative evaluation of Etest and sensititre yeastone panels against the clinical and laboratory standards institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents. J Clin Microbiol 45(3):698–706. https://doi.org/10.1128/JCM.01840-06 CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Clinical and Laboratory Standards Institute (2013) Reference method for broth dilution antifungal susceptibility testing of yeasts. Fourth Informat Suppl 32:1–23Google Scholar
- 19.Nakai T, Uno J, Ikeda F, Tawara S, Nishimura K, Miyaji M (2003) In vitro antifungal activity of micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms. Antimicrob Agents Chemother 47(4):1376–1381. https://doi.org/10.1128/aac.47.4.1376-1381.2003 CrossRefPubMedPubMedCentralGoogle Scholar